Atara Biotherapeutics, Inc.
ATRA
$15.63
$1.6511.80%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 202.41% | 475.53% | 1,404.02% | 2,111.34% | 809.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 202.41% | 475.53% | 1,404.02% | 2,111.34% | 809.03% |
| Cost of Revenue | -18.18% | -37.46% | -40.47% | -38.81% | -38.23% |
| Gross Profit | 166.19% | 139.15% | 96.89% | 80.13% | 62.00% |
| SG&A Expenses | -13.31% | -15.18% | -22.63% | -19.82% | -26.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.28% | -20.57% | -25.40% | -24.22% | -25.31% |
| Operating Income | 111.58% | 98.54% | 70.91% | 58.19% | 44.35% |
| Income Before Tax | 103.18% | 93.27% | 69.06% | 54.13% | 40.55% |
| Income Tax Expenses | -306.25% | -311.76% | -180.00% | 200.00% | -54.29% |
| Earnings from Continuing Operations | 103.20% | 93.29% | 69.07% | 54.12% | 40.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 103.20% | 93.29% | 69.07% | 54.12% | 40.55% |
| EBIT | 111.58% | 98.54% | 70.91% | 58.19% | 44.35% |
| EBITDA | 115.00% | 100.81% | 72.11% | 59.13% | 44.98% |
| EPS Basic | 99.00% | 93.03% | 80.29% | 63.01% | 46.76% |
| Normalized Basic EPS | 101.75% | 94.61% | 81.22% | 65.83% | 49.08% |
| EPS Diluted | 98.90% | 92.97% | 80.28% | 63.00% | 46.76% |
| Normalized Diluted EPS | 101.64% | 94.54% | 81.22% | 65.83% | 49.08% |
| Average Basic Shares Outstanding | 102.17% | 90.58% | 76.71% | 40.68% | 22.67% |
| Average Diluted Shares Outstanding | 103.16% | 91.05% | 76.71% | 40.68% | 22.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |